Ruby Trial & Quizartinib Toxicity
from OncoPharm Hosted by John Bossaer
The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 14 minutes long.
When was this OncoPharm episode published?
This episode was published on August 3, 2023.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.